IL13 and T-cell non-Hodgkin lymphoma: A previous preclinical study in mice found IL13 to inhibit the development of T-cell lymphoma and ovarian adenocarcinoma; this appeared to be facilitated by converting tumor-supporting macrophages to cytotoxic effectors [25].